Page 26 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

Chapter 1
69. Carpenter WT, Gruen PH. Cortisol’s effects on human mental functioning. J Clin psychopharm 1982;2:91-101.
70. Foster JM, McDonald VM, Guo M, Reddel HK. “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J. 2017,50(3) 1700765; DOI: 10.1183/13993003.00765-2017.
71. Broersen. J, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. J clin endocrinol metab. 2015; 100(6):2171-2180.
72. Arlt W, Allolio B. Adrenal insuficiency. Lancet 2003;361(9372):1881-1893.
73. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003;111:3-22.
74. Stanbury RM, Graham EM. Systemic corticoid therapy-side effects and their management. Br J Ophthalmol 1998;82:704-708.
75. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin immunol 2013;9:1-25.
76. Trivedi V, Apala DR, Iyer VN. Occupational asthma: diagnostic challenges and management dilemmas. Curr Opin Pulm Med. 2017;23(2):177–183.
77. Göksel O, Celik GE, Erkekol FO, Güllü E, Mungan D, Misirligil Z. Triggers in adult asthma: are patients aware of triggers and doing right? Allergol Immunopathol (Madr). 2009;37(3):122-8.
78. World Health Organization. Adherence to long-term therapies: evidence for action. 2003. www. who.int/chp/knowledge/publications/adherence_full_report.pdf. (last accessed December 2018).
79. Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012; 67:751–753.
80. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously.. Thorax. 2012;67(3):268-70.
81. Williams LK. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol 2010; 126:225-31,31 e1-4.
82. Foster JM. Identifying patient specific beliefs and behaviors for conversations about adherence in asthma. Inter Med J 2012;42:e136-44.
83. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respiratory Medicine 2011;105:1308-1315.
84. National Institute for Health and Clinical Excellence (NICE). Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence (CG76): Quick Reference Guide. http://guidance.nice.org.uk/CG76 (accessed December 2018).
85. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9.
86. Braunstahl G-J, Chlumský J, Peachey G, Chen C-W. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy, Asthma & Clinical Immunology 2013,9:47.
87. Rabe KF, Parameswaran N, Brusselle G, Maspero JF, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-85.
88. Grossman JM. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis care res 2010;62:1515-26.
89. Adler RA. Suggested guidelines for evaluation and treatment of glucocorticoid induced osteoporosis for the department of veterans affairs. Arch Intern Med 2003;163:2619-2624.
90. Ledford D, Apter A, Brenner AM, Rubin K, Prestwood K, Frieri M, Lukert B. Osteoporosis in the corticosteroidtreated patient with asthma. J Allergy Clin Immunol 1998;102:353-62.
91. Goodwin RD. Mental disorders and asthma in the community. Arch gen psychiatry 2003;60:1125- 30.
92. Prednisolone drug interactions. https://www.drugs.com/drug-interactions/prednisolone-index. html (last accessed December 2018).
93. Kountz DS, Clark CL. Safely withdrawing patients from chronic glucocorticoid therapy. Am Fam Physician. 1997;55(2):521-5, 529-30.
24